tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemophilia A D006467 10 associated lipids
Hemorrhage D006470 15 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Hepatitis C D006526 7 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hernia, Ventral D006555 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Herpesviridae Infections D006566 4 associated lipids
HIV Seropositivity D006679 15 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hydronephrosis D006869 4 associated lipids
Hyperalgesia D006930 42 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperglycemia D006943 21 associated lipids
Hyperkalemia D006947 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Metalidis C et al. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. 2011 Transplantation pmid:21544031
Ekberg H Calcineurin inhibitor sparing in renal transplantation. 2008 Transplantation pmid:18813097
Peterson LB et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. 1998 Transplantation pmid:9448137
Dumont FJ et al. A tacrolimus-related immunosuppressant with reduced toxicity. 1998 Transplantation pmid:9448138
Fischer L et al. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study. 2015 Transplantation pmid:26151607
Miyauchi T et al. Effect of donor-specific splenocytes via portal vein and FK506 in rat small bowel transplantation. 1998 Transplantation pmid:9448139
Rosen HR et al. Significance of early aminotransferase elevation after liver transplantation. 1998 Transplantation pmid:9448146
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Roth D et al. A prospective study of hepatitis C virus infection in renal allograft recipients. 1996 Transplantation pmid:8623154
Koprak S et al. Depletion of the mature CD4+8- thymocyte subset by FK506 analogs correlates with their immunosuppressive and calcineurin inhibitory activities. 1996 Transplantation pmid:8623162
Silva HT et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients. 2014 Transplantation pmid:24521771
Calmus Y et al. Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. 2010 Transplantation pmid:20495510
Ouyang J et al. Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. 2005 Transplantation pmid:15912108
Zoppo A et al. Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. 1999 Transplantation pmid:10551656
Egli A et al. Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. 2009 Transplantation pmid:19935369
Boyer O et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. 2005 Transplantation pmid:15912111
Abbott KC et al. New-onset gout after kidney transplantation: incidence, risk factors and implications. 2005 Transplantation pmid:16340779
Villanueva G and Baldwin D Rosiglitazone therapy of posttransplant diabetes mellitus. 2005 Transplantation pmid:16340782
Numakura K et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. 2005 Transplantation pmid:16340785
Cendales LC et al. Composite tissue allotransplantation: development of a preclinical model in nonhuman primates. 2005 Transplantation pmid:16340790
Khanna A et al. Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow. 1998 Transplantation pmid:9500620
Shihab FS et al. Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. 2009 Transplantation pmid:19202436
Gayowski T et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. 1998 Transplantation pmid:9500623
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Hirose R et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. 2000 Transplantation pmid:10670644
Hirano Y et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. 1992 Transplantation pmid:1373536
Takahara S et al. The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. 1992 Transplantation pmid:1373537
Johnson MC et al. QT prolongation and Torsades de Pointes after administration of FK506. 1992 Transplantation pmid:1373538
Yasunami Y et al. FK506 as the sole immunosuppressive agent for prolongation of islet allograft survival in the rat. 1990 Transplantation pmid:1691535
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Sindhi R et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. 2001 Transplantation pmid:11571449
Timmermann W et al. Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. 1999 Transplantation pmid:10401762
Jain A et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. 2000 Transplantation pmid:11087149
de Sandes-Freitas TV et al. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. 2015 Transplantation pmid:25929604
Fujimura Y and Owen RL Tacrolimus (FK506) and cyclosporine reduce the uptake and transport of particles into rabbit Peyer's patches. 2002 Transplantation pmid:11965030
Ciancio G et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. 2002 Transplantation pmid:11965039
Koomans HA and Ligtenberg G Mechanisms and consequences of arterial hypertension after renal transplantation. 2001 Transplantation pmid:11585243
Trimarchi HM et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. 1999 Transplantation pmid:10071024
Kaufman DB et al. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. 1999 Transplantation pmid:10071032
Khanna A et al. Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. 1999 Transplantation pmid:10071036
Bozorgzadeh A et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. 2004 Transplantation pmid:15087773
Benigni A et al. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. 1992 Transplantation pmid:1279848
Mor E et al. Late-onset acute rejection in orthotopic liver transplantation--associated risk factors and outcome. 1992 Transplantation pmid:1279849
Hirano Y et al. The effects of FK506 and cyclosporine on the exocrine function of the rat pancreas. 1992 Transplantation pmid:1279850
Diem HV et al. Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. 2003 Transplantation pmid:12777858
Smets F et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. 2002 Transplantation pmid:12042647
van Rijen MM et al. CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. 2002 Transplantation pmid:12042657
Bellon H et al. The Effect of Immunosuppression on Airway Integrity. 2017 Transplantation pmid:28471870
Kiuchi T CNIs: immediate benefits but storing problems for the future? 2008 Transplantation pmid:18946338
Couzi L et al. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. 2008 Transplantation pmid:18946343
Horner BM et al. Recipient damage after musculocutaneous transplant rejection. 2008 Transplantation pmid:18946349
Andoh TF et al. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. 1994 Transplantation pmid:7509514
Bäckman L et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. 1994 Transplantation pmid:7509516
Imado T et al. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. 2004 Transplantation pmid:14966413
Higgins RM et al. Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. 2004 Transplantation pmid:14966430
Woodle ES et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplantation pmid:8830821
Boillot O et al. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation: a pilot study. 1998 Transplantation pmid:9825815
Tanaka M et al. Effect of anticomplement agent K76 COOH on hamster-to-rat and guinea pig-to-rat heart xenotransplantation. 1996 Transplantation pmid:8830837
Opelz G Comparison of FK506 and cyclosporine. 1996 Transplantation pmid:8830844
Abadja F et al. Impact of mycophenolic acid and tacrolimus on Th17-related immune response. 2011 Transplantation pmid:21818055
Piao SG et al. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. 2014 Transplantation pmid:24825522
Jain AB et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. 1998 Transplantation pmid:9846530
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Herzog D et al. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. 2006 Transplantation pmid:16534467
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Pacifico L et al. Tacrolimus and food allergy. 2003 Transplantation pmid:14688538
Josephson MA et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. 2006 Transplantation pmid:16534472
Ochiai T et al. Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. 1989 Transplantation pmid:2474208
Ochiai T et al. Effects of combination treatment with FK506 and cyclosporine on survival time and vascular changes in renal-allograft-recipient dogs. 1989 Transplantation pmid:2474209
Hariharan S Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs). 2002 Transplantation pmid:12357988
Paty BW et al. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. 2002 Transplantation pmid:11884930
Dell'Antonio G and Randhawa PS "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. 1999 Transplantation pmid:10030300
Vyas S et al. Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. 1999 Transplantation pmid:10030303
Hanto DW and Chudzinski R What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? 2009 Transplantation pmid:19155968
Schena FP et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. 2009 Transplantation pmid:19155978
Gouraud A et al. Follow-up of tacrolimus breastfed babies. 2012 Transplantation pmid:22996303
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Muthukkumar S et al. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. 1995 Transplantation pmid:7544036
Muraki T et al. Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. 1995 Transplantation pmid:7544038
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplantation pmid:12499885
Fridell JA et al. Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. 2002 Transplantation pmid:12499888
Stevens C et al. The effects of immunosuppressive agents on in vitro production of human immunoglobulins. 1991 Transplantation pmid:1710843
Metcalfe S and Milner J Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. 1991 Transplantation pmid:1710844
Aw MM et al. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. 2003 Transplantation pmid:12660504
Pape E et al. Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. 2015 Transplantation pmid:26308424
Molmenti EP et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. 2001 Transplantation pmid:11213072
Sahara H et al. Beneficial effects of perioperative low-dose inhaled carbon monoxide on pulmonary allograft survival in MHC-inbred CLAWN miniature swine. 2010 Transplantation pmid:21076382
Min SI et al. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. 2010 Transplantation pmid:21076384
Chan L et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. 2008 Transplantation pmid:18360262
Saad ER et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. 2008 Transplantation pmid:18360267
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Lauzurica R et al. Tacrolimus-associated severe bilateral corneal ulcer after renal transplantation. 2002 Transplantation pmid:11923710
Bolley R et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. 2002 Transplantation pmid:11923712
Burger CI et al. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. 2010 Transplantation pmid:20440199
Wong W et al. 2005 immunosuppressive strategies in kidney transplantation: which role for the calcineurin inhibitors? 2005 Transplantation pmid:16082321
Mendez R et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. 2005 Transplantation pmid:16082323
Oku M et al. Hepatocyte growth factor sustains T regulatory cells and prolongs the survival of kidney allografts in major histocompatibility complex-inbred CLAWN-miniature swine. 2012 Transplantation pmid:22158517
Mayer AD et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. 1997 Transplantation pmid:9275110